StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.4
Power Rank trend -> Rising
07/08/2024 11:32:00 EST
Edwards Lifesciences Corp (EW)
Industry: Medical Devices
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, EW has been trading in a range between $93.34 and $86.10 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
EW is trading below resistance at $95.56, about 4% to the upside. There is support at $89.20 -3% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Edwards Lifesciences Corp $EW entered a Green zone 12 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $91.33, a potential down side of -1.07% from the recent price of 92.32. The stock is trading 4.12% (potential upside) below its 52 week high of $96.12 and 52.42 % (potential downside) above its 52 week low of $60.57 - based on the recent price.
Company Summary
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.
News
| Final Trades: Edwards Lifesciences, American Tower & TransDigm The Investment Committee discuss their top stocks to watch for the second half. Source: CNBC Television Wed, 26 Jun 2024 13:58:58 -0400 Sentiment: Neutral |
| HOLX vs. EW: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Hologic (HOLX) and Edwards Lifesciences (EW). But which of these two stocks offers value investors a better bang for their buck right now? Source: Zacks Investment Research Wed, 26 Jun 2024 12:45:43 -0400 Sentiment: Neutral |
| HOLX vs. EW: Which Stock Should Value Investors Buy Now? Investors looking for stocks in the Medical - Instruments sector might want to consider either Hologic (HOLX) or Edwards Lifesciences (EW). But which of these two stocks offers value investors a better bang for their buck right now? Source: Zacks Investment Research Mon, 10 Jun 2024 12:45:56 -0400 Sentiment: Positive |
| Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient's annulus size or sex. These data were presented during the late-breaking clini. Source: Business Wire Wed, 05 Jun 2024 11:45:00 -0400 Sentiment: Neutral |
| Becton Dickinson Buys Critical Care Unit From Edwards Lifesciences for $4.2B Shares of Becton Dickinson (BDX) advanced close to 3% Monday as the maker of syringes and other medical devices announced it was buying the Critical Care product unit of Edwards Lifesciences (EW) for $4.2 billion in cash. Source: Investopedia Mon, 03 Jun 2024 16:45:47 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 96.12 52 Week Low: 60.57 Beta: 1.11 50 Day MA: 88.123 200 Day MA: 80.4276 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0.036 Qtr Revenue Growth YOY: 0.095 Forward PE: 32.8947 Trailing PE: 39.7931